Impact of exacerbation history on future risk and treatment outcomes in chronic obstructive pulmonary disease patients: A prospective cohort study based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) A and B classifications

Ling Lin, Qing Song, Wei Cheng, Tao Li, Ping Zhang, Cong Liu, Xueshan Li, Yuqin Zeng, Xin Li, Dan Liu, Yan Chen, Shan Cai, Ping ChenJournal of Global Health 2024 · DOI

TL;DR

This study reveals that a history of exacerbations in COPD patients, even just one in the past year, significantly increases their risk of future exacerbations and mortality, particularly in GOLD B patients. Crucially, it suggests that triple inhaler therapy may offer greater benefits for these patients than current guidelines recommend.

What Problem Does This Paper Address?

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease characterized by symptoms like shortness of breath, coughing, and mucus production. Exacerbations, or flare-ups, are a major concern as they can lead to a faster decline in lung function, increased mortality, and a reduced quality of life. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification system helps stratify patients based on symptom burden and exacerbation history to guide treatment. However, the current GOLD guidelines, particularly for GOLD A and B patients (those with low symptom burden and low exacerbation risk), may not adequately capture the increased risk associated with even a single prior exacerbation. This paper aims to clarify the impact of exacerbation history on future outcomes and the effectiveness of different inhaled therapies within these GOLD A and B classifications, addressing a potential gap in personalized risk assessment and treatment strategies.

Methods

This was a prospective, observational cohort study conducted in China, utilizing data from the "Real World Research of Diagnosis and Treatment of COPD (RealDTC)" cohort. Patients were classified according to the GOLD 2023 guidelines, specifically focusing on GOLD A and B groups. These groups were further divided into subgroups: A0 and B0 (no exacerbations in the previous year) and A1 and B1 (one moderate exacerbation in the previous year). The study followed patients for outcomes including moderate-to-severe exacerbations, hospitalizations, frequent exacerbations (defined as at least two in the follow-up period), and all-cause mortality. Statistical analysis involved multivariate Cox regression to compare risks between groups and to assess the impact of different inhaled drug combinations (LAMA, ICS+LABA, LABA+LAMA, and ICS+LABA+LAMA) on these outcomes, adjusting for various demographic and clinical factors.

Datasets

The study utilized data from the "Real World Research of Diagnosis and Treatment of COPD (RealDTC)" cohort, a multicenter, prospective study in China. Data was collected from July 1, 2017, to December 31, 2022, with follow-up extending to December 2023 or until death. This dataset included 8318 eligible patients. No new benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • Exacerbation History is a Potent Predictor: Even a single exacerbation in the past year (GOLD A1 and B1) significantly elevates the risk of future exacerbations and mortality compared to patients with no prior exacerbations (GOLD A0 and B0). This challenges the notion that only patients with multiple exacerbations require intensified management.
  • GOLD B1 Patients Face Higher Mortality Risk: The study highlights that GOLD B1 patients not only have an increased risk of exacerbation but also a significantly higher risk of mortality compared to GOLD B0 patients.
  • Triple Therapy May Be Underutilized: For GOLD A1 and B1 patients, triple inhaler therapy (ICS, LABA, and LAMA) appears to offer a greater benefit in reducing exacerbations and mortality than previously assumed or currently recommended by guidelines, particularly when compared to LAMA monotherapy.
  • Subtle Differences in Risk: While the general trend shows increasing risk from A0 to E, the study noted that GOLD A1 patients had a higher risk of moderate-to-severe exacerbation than GOLD B0 patients, suggesting a nuanced risk stratification beyond simple GOLD group assignment.

Key Results

  • Increased Risk in Exacerbation History Groups:
    • GOLD A1 patients had a higher risk of moderate-to-severe exacerbation (HR=2.087), hospitalization (HR=1.704), and frequent exacerbation (HR=1.983) compared to GOLD A0.
  • GOLD B1 patients had a higher risk of moderate-to-severe exacerbation (HR=1.321) and mortality (HR=1.362) compared to GOLD B0.
  • Treatment Efficacy:
    • In GOLD A0, different inhaled drug regimens showed no statistical difference in outcomes.
  • In GOLD A1, ICS, LABA, and LAMA together reduced the risk of moderate-to-severe exacerbation compared to LAMA alone.
  • In GOLD B0, LABA and LAMA, as well as ICS, LABA, and LAMA, reduced the risk of moderate-to-severe exacerbation, hospitalization, frequent exacerbation, and mortality compared to LAMA alone.
  • In GOLD B1, LABA and LAMA, or ICS, LABA, and LAMA, showed a lower risk of moderate-to-severe exacerbation and hospitalization compared to LAMA alone. Triple therapy (ICS, LABA, LAMA) also reduced frequent exacerbation and mortality.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size in GOLD A1: The number of GOLD A1 patients was relatively small, potentially affecting the statistical power to detect differences in clinical outcomes with different inhalation drugs.
  • Residual Confounding: Despite adjusting for numerous factors, residual confounding from unmeasured variables like depression, environmental exposures, physical activity, diet, and adherence may still influence the results.
  • Chinese Cohort: The study's findings are based on a Chinese population, which may limit generalizability to other populations due to differences in healthcare systems, genetics, and environmental factors.

Future work could involve larger, multi-ethnic studies to confirm these findings and explore the impact of specific inhaled therapies in more detail across different GOLD classifications. The authors also suggest that these findings could inform more precise risk stratification and treatment recommendations for COPD patients.

Summary updated

Abstract

Compared to the GOLD A or B group without exacerbation history, GOLD A patients with exacerbation history had a higher risk of future exacerbation, and GOLD B patients with exacerbation history had a higher risk of future exacerbation and mortality and benefited more from triple inhaler therapy.
BibTeX
@article{lin2024impact,
  author = {Ling Lin and Qing Song and Wei Cheng and Tao Li and Ping Zhang and Cong Liu and Xueshan Li and Yuqin Zeng and Xin Li and Dan Liu and Yan Chen and Shan Cai and Ping Chen},
  title = {{Impact of exacerbation history on future risk and treatment outcomes in chronic obstructive pulmonary disease patients: A prospective cohort study based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) A and B classifications}},
  journal = {Journal of Global Health},
  year = {2024},
  doi = {10.7189/jogh.14.04202},
}
Figure